ERBB2 and breast carcinoma: Specifically, mTG conjugation of branched linkers on the heavy chain of an anti-HER2 monoclonal antibody have shown to increase the drug cytotoxicity against a HER2-expressing breast cancer cell line in vitro, compared to conjugates carrying the classic linear linkers [224].